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Abstract
Background: In advanced breast cancer, multiple sequential lines of treatments are frequently applied. Pegylated
liposomal doxorubicin (PLD) has a favourable toxicity profile and can be used in first or higher lines of therapy.
PLD has demonstrated response activity even after prior anthracycline exposure.
Methods: 129 consecutive patients with advanced breast cancer, of whom the majority had been massively
pretreated, received PLD as monotherapy within licensed approval, for which efficacy and toxicities were
documented.
Results: In a routine therapy setting, PLD was administered in a slightly reduced dose (median, 40 mg/m
2 per
cycle). Response rate (complete and partial remission) was 26%, and stable disease was observed in 19% of
patients. Progression-free (PFS) and overall survival (OS) were 5.8 months and 14.2 months, respectively. There was
no difference in terms of response and PFS, no matter if patients had already received anthracycline treatment.
Interestingly, PFS proved similar regardless whether PLD was administered as palliative therapy in first, second or
third line. Furthermore, PFS and OS were similar in patients with response or stable disease, underscoring the view
that disease stabilization is associated with a profound clinical benefit. The most common side effects reported
were palmar-plantar erythrodysesthesia (17%), exanthema (14%) and mucositis (12%).
Conclusions: Efficacy and toxicity data in these “real life” patients permit the conclusion that PLD is a valuable
option in the treatment of advanced breast cancer even in heavily pretreated patients.
Background
There are numerous systemic therapeutic options avail-
able for the tailored treatment of metastatic breast
cancer. In addition, therapeutic antibodies and small
molecules increasingly complement the therapeutic
range of instruments. The choice of systemic therapy fol-
lows accepted guidelines (1) but remains largely based on
individual factors (2). In case instant response is required,
such as rapidly progressive, threatening disease or mas-
sive symptoms, combination cytostatic therapy is usually
administered; more often, however, monotherapy is the
method of choice for patients in whom a long-term stabi-
lization of metastatic disease is the objective. Thus, differ-
ent therapies can be applied in sequence over a long
period of metastatic disease. Although evidence from
randomized studies is largely lacking in more advanced
disease, administration of multiple treatment lines (e.g.,
third line and higher) is clinical routine, often drawing
out remarkable clinical benefit. However, side effects and
cumulative toxicities have to be considered in the choice
of a cytostatic to be administered.
Pegylated liposomal doxorubicin (PLD; Caelyx, Aesca,
Vienna) is doxorubicin encapsulated in 85 nm vesicles
with a lipophilic surface including hydrophilic polyethy-
lene glycol. With this doxorubicin formulation, a pro-
longed circulation time and differential uptake in
abnormally permeable vessels with accumulation in tumor
tissue is observed (3). The main advantage of PLD, apart
from the clinical benefit provided for breast cancer, is a
reduced proportion of patients with classic anthracycline
side effects such as cardiotoxicity, hematotoxicity and alo-
pecia (4-10); on the other hand, PLD has been associated
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(PPE), which may prove to be dose-limiting after repeated
treatments (10-12).
In an Austrian phase II trial on PLD as second-line
monotherapy in metastatic breast cancer, encouraging
results with a high rate of clinical benefit at good tolerabil-
ity were achieved (4). Based on these encouraging results,
an observational study was undertaken in Austria to docu-
ment benefit and toxicities of PLD monotherapy in
patients with metastatic breast cancer and cardiac risk fac-
tors, who were treated in a routine use setting.
Methods
Inclusion criteria and treatment
In accordance with licensed approval and accepted guide-
lines for the treatment of advanced breast cancer (1),
PLD was administered as monotherapy in patients with
increased cardiac risk. In this survey on PLD use in
Austria, it was prespecified that patients had histologi-
cally confirmed, metastatic breast cancer with indication
for cytostatic therapy, were older than age 18, and har-
bored at least one of the following features which might
compromise cardiac function: age > 60 years; prior thor-
acic irradiation (including adjuvant irradiation of the
breast); prior anthracycline based therapy; hypertension;
and history of cardiac disease, such as infarction and con-
gestive heart failure. Echocardiography results were not
documented in this observational study. According to the
manufacturer’s recommendation, PLD was scheduled in
ad o s eo f5 0m g / m
2 once every 28 days for 6 cycles. In
this survey, aiming at analysing data on PLD use in breast
cancer treatment in a “real life” setting, PLD doses and
their modification were documented cycle by cycle. The
last follow-up data available for this analysis was obtained
on 29 September 2010, and the median observation time
in this study was 10.1 months.
This was an observational study with treatment of
breast cancer by PLD within licensed approval; thus,
adhering to the guidelines of the ethics committee of
Innsbruck Medical University, formal ethical approval
was not required at the time the trial was initiated.
Patients were routinely informed about the nature of
therapy, but written informed consent did not need to be
obtained.
Response evaluation
Patients who received at least one dose of PLD were
assessable for efficacy and safety. Response evaluation
was performed after two to four cycles ("mid term” sta-
ging) and after completion of therapy, i.e. after 6 cycles
as scheduled in the protocol or prior termination in case
of progressive disease (PD) or intolerable toxicity. Thus,
definitive response was determined at the end of PLD
therapy. However, to include temporary therapeutic
benefit, an alternative response evaluation was per-
formed, yielding “best response” which was documented
separately at both points in time. Response was evaluated
according to RECIST criteria for target and non-target
lesions, but no central review of radiogramm was con-
ducted. Progression-free survival (PFS) was defined as
time from first dose of PLD to disease progression or
death, whichever occurred first. Overall survival (OS) was
measured from initiation of PLD therapy until final
follow-up or death from any cause.
Statistical considerations
Comparison of response rates between patient subgroups
at baseline was carried out using Pearson’sc h i - s q u a r e
test. Event-related data (PFS and OS) were estimated
using the Kaplan-Meier method, and comparison of out-
comes between categorical subgroups was made using
the log-rank test. Univariate analysis was used to deter-
mine which baseline characteristics were associated with
PFS and OS. For those found to be associated with PFS
and OS (P ≤0.10), hazard ratios were calculated using the
multivariate Cox regression analysis. The significance
level was set at P < 0.05, in two-sided tests.
Results
Patient characteristics
129 patients who had received PLD as monotherapy in 18
Austrian centers were included in this survey between
2003 and 2009. Patient demographics and baseline charac-
teristics including previous therapies and setting of PLD
treatment are detailed in Table 1. Two men with meta-
static breast cancer were included. All patients were suf-
fering from stage IV breast cancer with different patterns
of metastasis. Most patients were characterized by two or
more cardiac risk factors; more precisely, 37 patients
(29%), 50 (39%), 34 (26%), 4 (3%), and 4 (3%), harbored
one, two, three, four or five cardiac risk factors, respec-
tively. Although PLD is licensed to be administered at a
dose of 50 mg/m
2 per cycle, PLD dose reductions on an
individual basis were frequently undertaken. At first cycle,
only a minority of patients (n = 46, 36%) received 50 mg/
m
2. Overall, median PLD dose per cycle was 40 mg/m
2,
and only 14 patients (11%) received the scheduled cumula-
tive PLD dose during 6 cycles of 300 mg/m
2.1 7p a t i e n t s
(13%) received more than six cycles (up to 16 cycles) as
extended or maintenance therapy (once every month [n =
9] or every second month [n = 8], respectively).
Response
Response to PLD was evaluated in 120 patients. In the
remaining 9 patients, response was not assessable due to
premature death (n = 4; fatal congestive heart failure [n =
1], refractory pleural effusion with fatal cardiopulmonal
failure [n = 1], end-stage disease and unknown reason in
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follow-up (n = 1). Upon termination of scheduled PLD
therapy (i.e., after 1 - 6 cycles), an objective response was
observed in 34/129 patients (ORR 26%), with CR and PR
in 2 (2%) and 32 (25%), respectively (Table 2). ORRs
according to patients’ characteristics and prior therapies
are detailed in Table 2. Of note, 24 patients (19%) who
suffered from PD after completion of therapy had PR
(n = 2) or SD (n = 22) during PLD therapy; considering
this temporary benefit in the “best response analysis”,
response was observed in 36 (28%) and disease stabiliza-
tion in 46 patients (36%). Thus, a clinical benefit from
PLD, at least a temporary one, was achieved in 82
patients (64%).
In line with a previous investigation (6), ORR upon
PLD was independent of prior anthracycline exposure.
However, ORR was significantly decreased in patients
who had previously received a taxane or both anthracy-
cline and taxane (Table 2).
In the 17 patients with extended PLD therapy (i.e., > 6
cycles), prolonged disease stabilization until termination
of PLD was observed in 10 patients, whereas the
remaining patients experienced disease progression
while on PLD.
Progression-free survival
At last update, 104 patients had documented PD, 4
patients died prematurely without documented PD (see
above), and 15 patients were alive without PD at the last
follow up. The remaining 6 patients died from breast
cancer, but their date of PD was unknown. Thus, for cal-
culation of PFS, these 6 patients were censored at the
date of last follow-up without PD. The median PFS for
all 129 patients after start of PLD therapy was 5.8
months, well in line with published data (4-10). Interest-
ingly, there was no difference in PFS whether PLD was
administered in first, second or third line palliative ther-
apy; however, PFS was significantly shorter when applied
in 4
th palliative line or beyond (Figure 1). Median PFS
according to different clinical characteristics are detailed
in Table 3. Prior administration of adjuvant or palliative
anthracyclines did not predict for shorter PFS to PLD
(Table 3). It was previously reported that disease stabili-
zation on PLD was a positive predictor of survival (8). In
line with those data, our results show that patients with
SD upon PLD did not differ from CR/PR patients with
respect to PFS (Figure 2). A subanalysis was performed in
those 48 patients who completed 6 cycles of PLD induc-
tion and achieved disease stabilization (SD or better);
among those, 17 received further PLD cycles as extended
or maintenance therapy (monthly and bi-monthly,
Table 1 Patient demographics and baseline
charactersitics (n = 129)
Characteristics N (%)
Median age (range), years 63 (34 - 86)
Median time from diagnosis to PLD (range), years 5.9 (0.1 - 26.7)
Distribution of metastasis
Bone 84 (65)
Liver 59 (46)
Lymph node 54 (42)
Lung 48 (37)
Skin and sof tissue 42 (33)
Pleura 30 (23)
Abdominal* 16 (12)
Brain 8 (6)
Others+ 7 (5)
Metastatic sites involved
One 19 (15)
Two 54 (42)
Three 26 (20)
Four or more sites 30 (23)
Cardiac risk factors
Prior anthracycline therapy 77 (60)
Age > 60 years 74 (57)
Hypertension 50 (39)
Prior thoracic irradiation† 39 (30)
History of cardiac disease 35 (27)
Median number of cardiac risk factors (range) 2 (1 - 5)
Previous therapies, setting
None 4 (3)
Endocrine, adjuvant 66 (51)
Endocrine, metastatic 84 (65)
Endocrine (adjuvant and/or metastatic) 95 (74)
Chemotherapy, adjuvant 77 (60)
Chemotherapy, metastatic 99 (77)
Chemotherapy (adjuvant and/or metastatic) 117 (91)
Anthracycline containing (adjuvant and/or
metastatic)
77 (60)
Taxane containing (adjuvant and/or metastatic) 73 (57)
Trastuzumab-containing (adjuvant/metastatic) 14 (11)
PLD line of chemotherapy‡
First 12 (9)
Second 32 (25)
Third 28 (22)
Fourth and higher 57 (44)
Median number of PLD cycles (range)§ 6 (1-6)
Median cumulative PLD dose, mg/m2 (range) § 210 (25 - 300)
*Including patients with peritoneal, ovarian and intestinal metastasis;
+pericardial (n = 3), bone marrow (n = 3) and meningeal involvement (n = 1);
†including patients with adjuvant irradiation of the breast;
‡adjuvant
chemotherapy was counted as prior therapy line
§PLD cycles within extension therapy (n = 17) not included.
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There was no difference in PFS in patients having
received more than 6 cycles compared to those having
received 6 cycles of PLD (Table 3).
Multivariate Cox regression analysis was performed,
and pretreatment baseline characteristics that showed
association with PFS in the univariate analysis (Table 3)
were included. Independent risk factors for shorter PFS
were: greater number (≥4) of metastatic sites (hazard
ratio, 1.66; 95% confidence interval [95%CI], 1.05-2.61;
P = 0.029); prior taxane-containing therapy (hazard
ratio, 1.52; 95%CI, 1.01-2.29; P = 0.044); and greater
number (≥4) of prior lines of therapy (hazard ratio, 1.79;
95%CI, 1.15-2.77; P = 0.009).
Overall survival
At the last follow up, 90 patients had died. Median OS
after inititiation of PLD was 14.2 months. OS was signif-
icantly shorter in patients with ≥4 metastatic sites and
≥4 prior therapy lines (Table 3). In contrast to PFS,
there was a trend towards shorter OS in patients who
had had prior anthracycline exposure. In analogy with
PFS, patients experiencing disease stabilization had simi-
lar OS to those with CR/PR. There was no difference in
OS in patients having received > 6 cycles when com-
pared with patients with clinical benefit who discontin-
ued PLD after 6 cycles (Table 3).
In multivariate Cox regression analysis (including the
characteristics “number of metastatic sites"; “number of
prior chemotherapies"; “prior anthracycline"; and “prior
endocrine therapy”), the occurrence of a greater number
(≥4) of metastatic sites was the only independent risk
factor for shorter OS (hazard ratio, 2.78; 95%CI, 1.75-
4.42; P < 0.001).
Therapies after PLD
Following disease progression after PLD, 79 patients
received another line of palliative systemic therapy,
Table 2 Response to PLD by baseline characteristics
Response according RECIST after completion of PLD
No. of patients (%)
Characterstic No. pts. CR PR SD PD NE ORR p
All patients 129 2 (2) 32 (25) 24 (19) 62 (48) 9 (7) 34 (26)
Age
< 63 64 0 (0) 15 (23) 11 (17) 36 (56) 2 (3) 15 (23) NS
> = 63 64 2 (3) 17 (27) 13 (20) 25 (39) 7 (11) 19 (30)
Age
< 50 17 0 (0) 3 (18) 2 (12) 11 (65) 1 (6) 3 (18) 0.382
≥50 112 2 (2) 29 (26) 22 (20) 51 (46) 8 (7) 31 (28)
No. cardiac risk factors
1 - 2 88 2 (2) 19 (22) 17 (19) 43 (49) 7 (8) 21 (24) 0.346
≥3 41 0 (0) 13 (32) 7 (17) 19 (46) 2 (5) 13 (32)
No. metastatic sites
1-3 99 2 (2) 28 (28) 21 (21) 42 (42) 6 (6) 30 (30) 0.065
4-7 30 0 (0) 4 (13) 3 (10) 20 (67) 6 (9) 4 (13)
Metastatic site
Visceral 92 0 (0) 22 (24) 15 (16) 49 (53) 6 (7) 22 (24) 0.321
Nonvisceral 37 2 (5) 10 (27) 9 (24) 13 (35) 3 (8) 12 (32)
Endocrine therapy
No 33 2 (6) 4 (12) 7 (21) 6 (49) 4 (8) 6 (18) 0.217
Yes 96 0 (0) 28 (29) 17 (18) 46 (48) 5 (5) 28 (29)
No. of prior chemos*
0 - 3 95 2 (2) 28 (30) 22 (23) 38 (40) 5 (5) 30 (32) 0.024
≥4 34 0 (0) 4 (12) 2 (6) 24 (71) 4 (12) 4 (12)
Prior anthracycline
No 52 2 (4) 12 (23) 14 (27) 19 (36) 5 (10) 14 (27) .904
Yes 77 0 (0) 20 (26) 10 (13) 43 (56) 4 (5) 20 (26)
Prior taxane
No 56 2 (4) 19 (34) 10 (18) 21 (38) 4 (7) 21 (38) 0.012
Yes 73 0 (0) 13 (18) 14 (19) 41 (56) 5 (7) 13 (18)
*adjuvant chemotherapy was counted as prior therapy line.
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the remaining 14 patients, status of subsequent therapy
is not known. The most common subsequent therapies
were: endocrine therapy (n = 20); single agent che-
motherapy (gemcitabine [n = 11]; taxane [11]; capecita-
bine [8]; platinum derivates [6], PLD reinduction [5];
vinorelbine [3]; non-pegylated liposomal doxorubicin
[1]; ralitrexed [1]), combination chemotherapy (CMF
[3]); chemotherapy in combination with monoclonal
antibodies (docetaxel/trastuzumab [1]; capecitabine/tras-
tuzumab [1]; capecitabine/bevacizumab [1]) or another
biologic compound (capecitabine/lapatinib [1]; capacita-
bine/bortezomib [1]; and monotherapy with a tyrosine
kinase inhibitor (lapatinib [1]; gefitinib [1]).
Safety
The most common side effect reported in this survey was
PPE, similar to published evidence, followed by exanthema
and mucositis (4, 5, 10, 11). Repeatedly reported side
effects are detailed in Table 4. Further adverse events were
apoplectic insult, herpes zoster, and panic attack (n = 1
each). We observed that PPE was significantly more preva-
lent in patients who received > 3 cycles PLD compared to
patients receiving only 1-3 cycles (22% vs 8%, P = 0.043).
Patients who achieved an objective response or at least SD
had PPE more frequently (26% vs 10%, P = 0.016).
Discussion
In this observational phase IV study, encouraging results
with single-agent PLD in metastasized breast cancer were
observed. It is a well known fact that a considerable por-
tion of patients with cancer would not be eligible for
inclusion in prospective studies (13), e.g. due to numer-
ous comorbidities and a large number of prior therapies;
moreover, data on efficacy of antineoplastic drugs in
unselected patients, often compromised by unfavorable
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Figure 1 Progression-Free Survival and line of palliative therapy. Kaplan-Meier plot illustrating progression-free survival (PFS) in patients
with metastasized breast cancer who received liposomal pegylated doxorubicin (PLD) monotherapy. Plotted according to line of palliative
treatment in which PLD was applied, median PFS was 7.8 months for patients treated with PLD in first line, 7.1 months in second line, 7.4
months in third line, and 5.0 months in fourth or higher line, which was significantly different when pooled over strata (P = 0.010). Interestingly,
pairwise comparisons showed no PFS difference between patients with PLD in first, second or third line. However, PFS was shorter for patients
in fourth or higher line of PLD (when compared with first line: P = 0.012; second line: P = 0.004; third line: P = 0.095).
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authors’ ongoing efforts to study effects of various treat-
ments in a range of malignancies in a “real life” setting
(14-18). Thus, we aimed at defining the role of PLD in
129 consecutive breast cancer patients who were treated
within the licensed approval. It must be noted that in an
observational study such as ours, patients differ from
those in prospective studies. This is especially true with
respect to basic characteristics (in the study presented
here, there were no exclusion criteria) and in-study pro-
cedures. For example, the interval of regular restaging
was not strictly pre-specified, a fact which may influence
PFS to a certain extent.
We were able to demonstrate that therapeutic results
and toxicity rates observed in prospective studies trans-
late nicely into the routine setting (4-11). In the course of
data documentation, it was verified that the participating
institutions started PLD therapy along the proposed
guidelines of administration and had their patients under
tight clinical control. Generally, however, we realized that
individualization of PLD schedule, predominantly
through dose reductions, was frequently carried out, well
Table 3 Univariate analysis for association of baseline characteristics and therapeutic response with PFS and OS from
start of PLD
Characteristics Number of patients Median PFS, months P value Median OS, months P value
All 129 5.8 14.2
Age
< 63 64 5.7 0.147 12.5 0.776
≥63 64 7.3 14.6
Age
< 50 17 4.0 0.247 16.6 0.880
≥50 112 6.0 14.2
No. cardiac risk factors
1 - 2 88 5.3 0.997 14.5 0.163
≥3 41 6.4 11.1
No. metastatic sites
1-3 99 7.1 0.021 15.3 < 0.001
4-7 30 3.6 6.0
Metastatic site
Visceral 92 5.4 0.034 12.5 0.618
Nonvisceral 37 9.8 14.3
Prior endocrine therapy
No 33 5.4 0.305 14.8 0.061
Yes 96 6.0 12.4
No. of prior chemos
+
0 - 3 95 7.3 0.001 14.5 0.01
≥4 34 5.0 10.1
Prior anthracycline
No 52 7.8 0.104 15.1 0.057
Yes 77 5.7 10.1
Prior taxane
No 56 7.8 0.036 14.3 0.392
Yes 73 5.4 12.5
Response
CR/PR 34 10.0 < 17.5 < 0.001
SD 24 11.9 0.001 24.6
PD 62 2.8 8.6
NE 9 2.4 3.0
PLD extension*
6 cycles, no extension 31 9.8 0.466 21.3 0.516
> 6 cycles 17 10.9 24.2
*Patients who achieved SD, PR or CR after scheduled PLD (i.e., 6 cycles).
+Adjuvant chemotherapy was counted as prior therapy line.
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20). In fact, the median dose of PLD administered was 40
mg/m
2 per cycle. This dose is less toxic than the licensed
50 mg/m
2 per cycle, obviously without compromising
therapeutic efficacy (20). Thus, we are convinced that the
results presented in our study reflect what is achievable
in breast cancer treatment in the routine setting. The
data presented here could serve as a benchmark for other
surveys on the use of cytostatic monochemotherapy in
breast cancer.
We found comparatively low objective response rates
and a comparatively high proportion of patients with
minor response and disease stabilization, qualifying for
SD. Age, prior endocrine or anthracycline therapy did not
affect response probability, and response rates were identi-
cal between chemo-naive patients and those with one to
three prior chemotherapy lines. However, response rate
was significantly lower in patients who had had four or
more prior therapy lines, a cohort which was relatively
large in this survey (26%, Table 2). We observed a higher
ORR in the patients who could receive the full course of
scheduled six PLD cycles (31/67 patients [49%]), and it
became evident that response to PLD can manifest rela-
tively late during therapy. Thus, 9 of the 31 responding
patients (29%) had SD in the mid-term staging after two
to four cycles.
It appeared that PLD therapy offered favorable survival
benefit in the different lines of treatment, comparable up
to the third line of palliative therapy, a fact that has not
been described yet (Figure 1). This suggests that PLD is a
reasonable treatment option even in higher treatment
lines when other cytostatic drugs are no longer promising.
However, by multivariate analysis, escalating refractoriness
also towards PLD, if administered in fourth and higher
line, is highlighted; likewise, inferior clinical efficacy by
PLD is observed in extraordinarily advanced disease, with
4 or more different metastatic sites involved. Nevertheless,
we observed impressive disease stabilizations in a number
36 30 24 18 12 6 0
Months after start of PLD
1,0
0,8
0,6
0,4
0,2
0,0
P
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
 
s
u
r
v
i
v
a
l
PD, n = 62
CR/PR, n = 34
SD, n = 24
NE, n = 9
P <0.001
Figure 2 Progression-Free Survival related to response. Kaplan-Meier plot illustrating progression-free survival (PFS) in patients with
metastasized breast cancer who received liposomal pegylated doxorubicin (PLD) monotherapy. Plotted according to radiographic response after
completion of PLD, median PFS was 10.0 months for patients with complete (CR) or partial rememission (PR), 11.9 months with stable disease
(SD), 2.8 months with progressive disease (PD), and 2.4 months in which response could not be evaluated (NE), which was significantly different
when pooled over strata (P < 0.001). Pairwise comparisons showed no PFS difference between patients with CR/PR and SD.
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and future work should focus on defining features predict-
ing therapeutic efficacy in such patients.
Patients experienced profound benefit in terms of PFS
and OS if they responded to or, more interestingly, had
disease stabilization through PLD therapy (Figure 2). This
underscores the observation that the achievment of SD by
systemic therapy is frequently associated with profound
clinical benefit not solely by symptom improvement and
gain in quality of life, but also by prolongation of survival
(8, 14, 21, 22). In this observational trial, we did not find
any indication that extending therapy beyond 6 cycles
could be beneficial in terms of PFS or OS. In the GEI-
CAM 2001-01 study, PLD was given as switch mainte-
nance therapy after first line induction by doxorubicin
followed by docetaxel. A modest prolongation of time to
next therapy but not of OS was observed (23); a general
recommendation for PLD use as maintenance therapy
cannot be given (24).
In this study, frequencies of toxicities induced by PLD
are within the range of expectations (4, 5, 10-12, 19). The
typical side effects of PLD therapy, PPE and exanthema
(Table 4), appeared to be of minor relevance, probably
due to the intensified managment of these toxicities
according to the manufacturer’s recommendations and
published guidelines (25). The lower median dose of PLD
may add to this observation (20). The patients in this
observational study harbored, to varying extents, cardiac
risk. The percentage of patients with cardiac toxicities
was small; however, two severe cardiac events (left ventri-
cular dysfunction) occurred during PLD treatment phase,
one of which was fatal. Thus, it is emphasized that close
monitoring of patients with cardiac risk factors is essen-
tial during cytostatic chemotherapy, by frequent clinical
examination, and repeated echocardiography and labora-
tory testing (e.g. NT-proBNP)(26). Grade IV neutropenia
and thrombocytopenia occurred in three patients and
two patients, respectively; two of them were massively
affected by bone marrow carcinosis and, thus, had
impaired hematopoietic reserve. Remarkably, partial
regeneration of hematopoiesis was achieved after 3 cycles
of dose-reduced PLD applications in one of the two
patients with grade IV thrombocytopenia.
Conclusion
The results of this observational study in metastatic
breast cancer document well the role of PLD in clinical
practice. PLD is a valuable single-agent treatment option
in advanced breast cancer, and particularly, for patients
with cardiac risk factors and those who had prior thera-
pies including anthracycline.
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